Biomarkers for Ventilator-associated Pneumonia
Key facts
- Who runs it
- Region Skane
- Where
- Norway, Portugal, and Sweden5 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 15 Oct 2021
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 3 groups
- Treatments tested
- Heparin-binding protein
- Interleukin-26
- Microbiome
- Bacterial transcriptome
- Proteome
- Record updated
- 26 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Admission to an intensive care unit
- Intubation within last 24 hours
- Anticipated mechanical ventilation of at least 48 hours
Who cannot take part
- Ongoing infection of the lungs at admission to the ICU
- Severe coagulopathy (spontaneous PK(INR) >1.8 or thrombocytes <50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors/NOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection
- FiO2 above 70% or PEEP above 15
- Severely elevated or instable intracranial pressure
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.
The 3 groups in the trial
- VAP
Enrolled participants that fully meet the criteria of VAP.
Treatment: Heparin-binding protein, Interleukin-26, Microbiome, Bacterial transcriptome, and Proteome
- Suspect VAP
Enrolled participants that develop signs of VAP but lack some variable, for instace new radiographic infiltrate or microbiological finding compatible with VAP.
Treatment: Heparin-binding protein, Interleukin-26, Microbiome, and Proteome
- No VAP
Enrolled participants that do not develop VAP.
Treatment: Heparin-binding protein, Interleukin-26, Microbiome, and Proteome
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia
- Record updated
- 26 June 2026